Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celldex Therapeutics Inc CLDX

Healthcare Biotechnology
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody... see more

Recent & Breaking News (NDAQ:CLDX)

Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

GlobeNewswire February 16, 2023

Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference

GlobeNewswire February 15, 2023

Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023

GlobeNewswire February 3, 2023

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022

GlobeNewswire December 6, 2022

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

GlobeNewswire December 2, 2022

Celldex to Participate in Upcoming November Investor Conferences

GlobeNewswire November 10, 2022

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2022

Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2022

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

GlobeNewswire July 21, 2022

Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

GlobeNewswire June 30, 2022

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

GlobeNewswire June 21, 2022

Celldex Announces Two New Appointments to its Board of Directors

GlobeNewswire June 16, 2022

Celldex to Present at the 2022 Jefferies Global Healthcare Conference

GlobeNewswire June 6, 2022

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022

GlobeNewswire May 19, 2022

Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 5, 2022

Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire February 28, 2022

Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call

GlobeNewswire February 22, 2022

Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 10, 2022

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

GlobeNewswire December 8, 2021

Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021

GlobeNewswire November 12, 2021